Intercept Pharmaceuticals Inc (was acquisited by Alfasigma (Italy) on 08/11/2023) (ICPT)
(10% Negative) Intercept Pharmaceuticals, Inc. (ICPT) Announces Delay in announced Trials for OCA in liver fibrosis due to NASH Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
📋 Intercept Pharmaceuticals, Inc. (ICPT) - Clinical Trial Update
Filing Date: 2022-07-07
Accepted: 2022-07-07 07:30:58
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (Intercept Pharmaceuticals, Inc.):
💼 Business Developments:
Structured Data: